A Phase 3 Randomized, Open-Label Study comparing Pexa-Ve

Project: Research project

Project Details

Description

A Phase 3 Randomized, Open-Label Study comparing Pexa-Vec (Vaccinia Gm-CSF/Thymidine Kinase- Deactivated Virus) followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy
StatusActive
Effective start/end date1/1/169/30/20

Funding

  • SILLAJEN USA, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.